News coverage about Albany Molecular Research (NASDAQ:AMRI) has trended somewhat positive this week, AlphaOne Sentiment Analysis reports. AlphaOne, a subsidiary of Accern, ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Albany Molecular Research earned a news sentiment score of 0.07 on AlphaOne’s scale. AlphaOne also assigned news stories about the biotechnology company an impact score of 70 out of 100, meaning that recent press coverage is likely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted AlphaOne Sentiment Analysis’s rankings:
- SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Albany Molecular Research, Inc -AMRI (finance.yahoo.com)
- Albany Molecular Research, Inc. (NASDAQ:AMRI) Investor Investigation of Takeover (sbwire.com)
- Analysts at JP Morgan Give Albany Molecular Research (NASDAQ:AMRI) a Downgrade (campdesrecrues.com)
- INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Albany Molecular Research, Inc. and Encourages Investors to Contact the Firm for Additional Information (finance.yahoo.com)
- The Law Offices of Vincent Wong Reminds Investors of an Investigation of Albany Molecular Research, Inc. in Connection with the Sale of the Company to GTCR LLC and The Carlyle Group (finance.yahoo.com)
A number of research firms recently issued reports on AMRI. First Analysis downgraded Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday. J P Morgan Chase & Co downgraded Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. William Blair downgraded Albany Molecular Research from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 6th. Finally, Morgan Stanley downgraded Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective for the company. in a report on Thursday, May 11th. They noted that the move was a valuation call.
Albany Molecular Research (NASDAQ AMRI) traded up 0.32% on Friday, hitting $21.64. The company had a trading volume of 1,181,602 shares. Albany Molecular Research has a one year low of $12.51 and a one year high of $22.17. The company’s market capitalization is $900.31 million. The stock’s 50-day moving average price is $18.69 and its 200 day moving average price is $17.04.
Albany Molecular Research (NASDAQ:AMRI) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. The business had revenue of $163.80 million during the quarter, compared to analyst estimates of $161.43 million. During the same period in the previous year, the company posted $0.07 EPS. The firm’s revenue was up 55.1% compared to the same quarter last year. On average, analysts expect that Albany Molecular Research will post $1.13 EPS for the current fiscal year.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-positive-press-coverage-likely-to-affect-albany-molecular-research-amri-share-price/1916576.html
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.